Arkolith/Insider Trading/RXRX/Form 4

Khan Najat

Chief R&D Commercial Officer, DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Dec 29, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$549K
Net Open-Market Flow
-$549K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 22, 2025Sell(S)124K$4.41$549K611K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001601830-25-000176) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML